NicOx's naproxcinod needs long-term safety data, US FDA panel says
This article was originally published in Scrip
NicOx's anti-inflammatory agent naproxcinod requires further safety data, including long-term cardiovascular outcomes, prior to approval as an osteoarthritis treatment, the US FDA's outside advisors said at a meeting on 12 May.
You may also be interested in...
FDA's recommendation that COVID-19 vaccine sponsors conduct two months of median follow-up to support an emergency use authorization may not be long enough, some experts say in what can be viewed as validation for agency's position in battle with White House.
There are 18 people on the committee that will issue the first recommendations on COVID-19 vaccine development and licensure. Among the experts are a University of Michigan epidemiologist who will serve as acting chairman and seven temporary voting members, two of whom required conflict-of-interest waivers.
Unlike AMAG's Makena, nearly all the products that have seen their accelerated approvals pulled have left the market quietly, our infographic shows.